Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

NCT02365766 is registered in ClinicalTrials.gov with Jason R. Brown as lead sponsor.

NCT NCT02365766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02365766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Lead sponsor
Jason R. Brown
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2015
Completion date
February 23, 2024
Enrollment
83 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urothelial carcinoma